NCI must make a bigger investment in new cancer therapies and expand the clinical trials system that tests them, the institute’s Acting Director Douglas Lowy said in his remarks at the American Society of Clinical Oncology annual meeting June 4.
NCI has truncated the just-renewed five-year Cancer Center Support Grant held by Wake Forest Baptist Comprehensive Cancer Center as that institution undergoes a bumpy transition of leadership—in the midst of a challenging integration with Atrium Health Levine Cancer Institute.
In testimony before the House Labor HHS Appropriations Subcommittee May 26, cancer organizations recommended FY23 appropriations of $49 billion for NIH, $7.76 billion for NCI, and $426.6 million for the CDC’s Division of Cancer Prevention and Control.
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, according to a large epidemiologic study led by NCI researchers.
The same House appropriators who, with bipartisan resolve, oversaw years of dramatic funding increases for NIH expressed equally bipartisan misgivings about President Joe Biden’s proposal to boost funding for the Advanced Research Projects Agency for Health while giving NIH a meager raise—and cutting funds for NCI.
Before any strategy can be formulated for next year’s appropriations, cancer groups must confront the formidable challenge of figuring out how much of President Joe Biden’s vision for cancer research is realistic.
Portage Biotech Inc., NCI, and Stimunity entered a Cooperative Research and Development Agreement, under which they will collaborate with NCI’s Center for Cancer Research to advance preclinical and potential clinical development of STING agonists and anti-Receptor for Advanced Glycation End products (RAGE) agents to enhance the efficacy of cancer vaccines developed in the NCI CCR Vaccine Branch.
After nearly five years in the federal government—at both NCI and FDA—Ned Sharpless is stepping down from his position as NCI director.
The NCI Board of Scientific Advisors approved nine new and reissued concepts at a meeting held March 28-29.
On March 31, NCI officially renewed the University of Colorado Cancer Center’s “comprehensive” designation with a strong rating, the best ever received at the CU Cancer Center.
